Objective To investigate the effect of omalizumab on serum helper T lymphocytes,the balance of T-helper cell type 1(Th1)/T-helper cell type 2(Th2),cellular inflammatory factors and disease control in patients with allergic rhinitis.Methods A total of 86 patients with allergic rhinitis admitted to Hangzhou Xiaoshan Hospital of Traditional Chinese Medicine from March 2021 to January 2022 were selected and randomly divided into observation group and control group by single-blind random number table method,with 43 cases in each group.Patients in control group received conventional drug treatment,while those in observation group were treated with omalizumab in addition to the treatment of control group.The nasal symptom scores,clinical efficacy,disease control effect,related symptom scores,Th1/Th2,serological indicators and adverse reactions of two groups were compared.The patients were followed up for 2 years to record the recurrence situation.Results After treatment,the symptom scores of sneezing,nasal congestion,runny nose,and nasal itching,visual analogue scale(VAS),rhinoconjunctivitis quality of life questionnaire(RQLQ),serum immunoglobulin E(IgE),interleukin-4,Th2 levels and recurrence rates of both groups were all lower than those before treatment,and those of observation group were lower than those of control group(P＜0.05).After treatment,the asthma control test(ACT)scores,Th1,Th1/Th2,and gamma interferon(IFN-γ)levels of both groups were all higher than those before treatment,and those of observation group were higher than those of control group(P＜0.05).The total effective rate of observation group was higher than that of control group after treatment(P＜0.05).Conclusion Omalizumab can improve the nasal symptoms and quality of life of patients with allergic rhinitis,regulate the Th1/Th2 balance,reduce the inflammatory response,lower the serum IgE level,and has a definite disease control effect,is safe and reliable,and has a good long-term prognosis.

Objective To investigate the effect of omalizumab on serum helper T lymphocytes,the balance of T-helper cell type 1(Th1)/T-helper cell type 2(Th2),cellular inflammatory factors and disease control in patients with allergic rhinitis.Methods A total of 86 patients with allergic rhinitis admitted to Hangzhou Xiaoshan Hospital of Traditional Chinese Medicine from March 2021 to January 2022 were selected and randomly divided into observation group and control group by single-blind random number table method,with 43 cases in each group.Patients in control group received conventional drug treatment,while those in observation group were treated with omalizumab in addition to the treatment of control group.The nasal symptom scores,clinical efficacy,disease control effect,related symptom scores,Th1/Th2,serological indicators and adverse reactions of two groups were compared.The patients were followed up for 2 years to record the recurrence situation.Results After treatment,the symptom scores of sneezing,nasal congestion,runny nose,and nasal itching,visual analogue scale(VAS),rhinoconjunctivitis quality of life questionnaire(RQLQ),serum immunoglobulin E(IgE),interleukin-4,Th2 levels and recurrence rates of both groups were all lower than those before treatment,and those of observation group were lower than those of control group(P＜0.05).After treatment,the asthma control test(ACT)scores,Th1,Th1/Th2,and gamma interferon(IFN-γ)levels of both groups were all higher than those before treatment,and those of observation group were higher than those of control group(P＜0.05).The total effective rate of observation group was higher than that of control group after treatment(P＜0.05).Conclusion Omalizumab can improve the nasal symptoms and quality of life of patients with allergic rhinitis,regulate the Th1/Th2 balance,reduce the inflammatory response,lower the serum IgE level,and has a definite disease control effect,is safe and reliable,and has a good long-term prognosis.